4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	88.24	85.21	0.04	20.72	3.13	18.04
Revenue Growth	383560.87%	230194.59%	-99.82%	562.29%	-82.65%	32.52%
Gross Profit Gross Profit Growth	88.24	85.21	0.04	20.72	3.13	18.04
Operating Income Operating Income Growth	-179.55	-159.55	-187.84	-112.87	-110.03	-71.33
Net Income Net Income Growth	-160.9	-140.11	-160.87	-100.84	-107.49	-71.32
Earnings Per Share EPS Growth	-2.57	-2.42	-2.98	-2.58	-3.32	-2.57
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Japan Japan Growth	-	85	-	-	-	-
United States United States Growth	0.29	0.21	0.04	20.16	0.04	0.12
Total Total Growth	88.24	85.21	0.04	20.72	3.13	18.04

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	390.89	402.66	424.88	288.23	213.55	247.78
Total Debt Total Debt Growth	20.54	21.41	24.61	14.67	16.12	16.45
Net Cash (Debt) Net Cash Growth	370.36	381.24	400.27	273.56	197.43	231.33
Net Cash Growth	24.45%	-4.75%	46.32%	38.56%	-14.65%	-16.41%
Net Cash Per Share Net Cash Per Share Growth	6.07	6.58	7.42	6.99	6.10	8.34

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-129.45	-109.08	-134.59	-75.79	-86.69	-69.13
Capital Expenditures CapEx Growth	0.11	-0.54	-3.79	-2.77	-11.54	-9.11
Free Cash Flow Free Cash Flow Growth	-129.34	-109.62	-138.37	-78.56	-98.22	-78.24
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-203.47%	-187.24%	-507678.00%	-544.65%	-3516.52%	-395.46%
Pretax Margin	-182.31%	-164.43%	-434778.38%	-486.59%	-3435.41%	-395.37%
Profit Margin	-182.31%	-164.43%	-434778.00%	-486.59%	-3435.41%	-395.37%
FCF Margin	-146.58%	-128.65%	-373976.00%	-379.11%	-3139.05%	-433.77%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 25, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PS Ratio	5.97	5.07	6893.84	42.11	231.59	39.20

Data Sources: Fiscal.ai and S&P Global Market Intelligence Last updated: May 7, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company. Revenue segment data is provided by S&P Global Market Intelligence.

Update frequency:

Quarterly

Last checked:

Jul 25, 2026

Data Sources Report a data error